+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Antibodies Contract Manufacturing Market by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies), Source (Mammalian, Microbial), Services, End-User - Forecast 2024-2030- Product Image
Global Antibodies Contract Manufacturing Market by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies), Source (Mammalian, Microbial), Services, End-User - Forecast 2024-2030- Product Image
Sale

Global Antibodies Contract Manufacturing Market by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies), Source (Mammalian, Microbial), Services, End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5715633
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antibodies Contract Manufacturing Market size was estimated at USD 16.34 billion in 2023, USD 18.04 billion in 2024, and is expected to grow at a CAGR of 10.82% to reach USD 33.56 billion by 2030.

Antibodies contract manufacturing includes the outsourcing of antibody production and purification processes to specialized service providers. This approach allows biotechnology and pharmaceutical companies to leverage external expertise and advanced facilities for the production of monoclonal, polyclonal, and recombinant antibodies without the need for significant capital investments in infrastructure. Antibodies contract manufacturing services typically cover a broad spectrum of processes, including cell line development, upstream and downstream processing, purification, and final formulation.

The growing emphasis on antibody-based drugs in the treatment of chronic diseases such as cancer, autoimmune diseases, and infectious diseases significantly fuels the need for specialized manufacturing services. Increasing regulatory support for innovative therapeutic antibodies, combined with streamlined approvals for biologics, promotes partnerships with contract manufacturing organizations (CMOs). Intellectual property concerns with rising quality and compliance risks associated with antibody contract manufacturing is restraining the growth of the market. Technological progress in bioprocessing, genetic engineering, and high-throughput screening accelerates the development of novel antibodies, creating opportunities for market growth.

Regional Insights

The Americas represents a highly developing landscape for the global antibodies contract manufacturing market attributed to the region's robust biopharmaceutical research landscape, significant healthcare spending, and supportive regulatory environment. The US houses several significant contract manufacturing organizations (CMOs) that offer a wide range of services, from early-stage development to large-scale production. Canada and Brazil are also witnessing growth in this sector, though the US continues to lead in terms of market size and technological advancements.

The antibody contract manufacturing market in Asia-Pacific is fueled by increasing investment in biotechnology, rising demand for biosimilars, and improving healthcare infrastructure. Countries such as China, South Korea, and India are at the forefront, with their governments implementing favorable policies for biotech advancements. China, in particular, has seen a surge in the establishment of CMOs and contract development and manufacturing organizations (CDMOs) owing to its large patient population and growing biotech industry. The region offers cost-competitive services, which, combined with improving quality standards, makes it an attractive location for outsourcing antibody production. The EMEA region exhibits a strong presence in the antibodies contract manufacturing market, with Europe leading the way due to its highly developed biopharmaceutical sector. Countries including Germany, the United Kingdom, and Switzerland are notable for their sophisticated biotech ecosystems, comprising both established players and emerging biotechs. The presence of stringent regulatory standards ensures high-quality manufacturing processes and outputs. The Middle East and Africa are gradually catching up, with investments in healthcare infrastructure and an increasing focus on biotechnology research.

Market Trends by Segment

  • Antibody Type: Growing need for monoclonal antibodies due to their uniformity, specificity, and large-scale production capabilities
  • End-User: Rising adoption of antibodies contract manufacturing among biotechnology & pharmaceutical firms to leverage specialized expertise in antibody production and purification

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

Samsung Biologics and LegoChem Biosciences Forge Strategic Alliance to Accelerate ADC Innovation for Solid Tumor Treatment

Samsung Biologics and LegoChem Biosciences entered into a strategic partnership to advance the development and manufacturing of antibody-drug conjugates (ADCs) for the treatment of solid tumors. This collaboration is poised to enhance the submission of an Investigational New Drug application to the FDA by early 2025. Samsung Biologics will extend its expertise in antibody development and drug substance production to bolster LegoChem Biosciences’ ADC initiatives.

Aragen Invests USD 30 Million in Bangalore Facility to Boost Biologics Manufacturing Capabilities

Aragen committed to a USD 30 million investment to establish an advanced biologics manufacturing facility in Bangalore, India. Spanning 160,000 m2, this state-of-the-art facility is poised to house process development laboratories and a series of Good Manufacturing Practice (GMP) suites, complemented by Quality Control labs for analytical and microbiological testing. Designed to support the entire biomanufacturing lifecycle, from process development to large-scale drug substance production, the facility aims to enhance Aragen's offerings in monoclonal antibodies, therapeutic proteins, and fusion protein production.

KBI Biopharma Unveils SUREmAb, Monoclonal Antibody Development with Accelerated Manufacturing Solutions

KBI Biopharma, Inc., a subsidiary of JSR Life Sciences, announces the introduction of SUREmAb, a service based on the proven SUREtechnology Platform, designed to enhance monoclonal antibody (mAb) development and manufacturing. This comprehensive solution accelerates the biopharmaceutical manufacturing process by offering rapid development of research cell banks in just 9 weeks and enabling the transition from DNA to GMP drug substance in a mere 11 months.

Key Company Profiles

The report delves into recent significant developments in the Antibodies Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Abeomics, Absolute Antibody by LSBio, Advanced ChemTech, Inc., AGC Biologics, Antibodies, Inc., AstraZeneca, Boehringer Ingelheim Biopharmaceuticals GmbH., Bryllan LLC, Catalent, Inc., CD BioSciences, Charles River Laboratories International, Inc., Eli Lilly and Company, FUJIFILM Holdings Corporation, Fujirebio Inc. by H.U. Group Holdings, Inc., Hycult Biotechnology (H.B.T.) B.V., Labcorp Drug Development, Lonza Group Ltd., Merck KGaA, Molecular Depot LLC, Pierre Fabre S.A, Samsung Biologics, Sapphire Bioscience Pty. Ltd., Scantibodies Laboratory, Inc., Synthon International Holding B.V., The Serum Institute of India, and WuXi Biologics Co., Ltd.

This research report offers invaluable insights into various crucial aspects of the Antibodies Contract Manufacturing Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Development and commercialization need for biopharmaceutical therapeutics
5.1.1.2. Surging need for advanced antibodies for the treatment of chronic diseases
5.1.1.3. Rising preference for personalized medicines
5.1.2. Restraints
5.1.2.1. Concerns regarding development and manufacturing of biologics
5.1.3. Opportunities
5.1.3.1. Growing number of biologics pipelines and growing contract manufacturing service
5.1.3.2. Increasing the R&D budget for the production of antibodies globally
5.1.4. Challenges
5.1.4.1. Complexity of bi/multispecific antibody formats
5.2. Market Segmentation Analysis
5.2.1. Antibody Type: Growing need for monoclonal antibodies due to their uniformity, specificity, and large-scale production capabilities
5.2.2. End-User: Rising adoption of antibodies contract manufacturing among biotechnology & pharmaceutical firms to leverage specialized expertise in antibody production and purification
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Antibodies Contract Manufacturing Market, by Antibody Type
6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Polyclonal Antibodies
7. Antibodies Contract Manufacturing Market, by Source
7.1. Introduction
7.2. Mammalian
7.3. Microbial
8. Antibodies Contract Manufacturing Market, by Services
8.1. Introduction
8.2. Analytical Development & Quality Control
8.3. Cell Line Development
8.4. Process Development
9. Antibodies Contract Manufacturing Market, by End-User
9.1. Introduction
9.2. Academics & Research Institutions
9.3. Biotechnology & Pharmaceuticals Companies
10. Americas Antibodies Contract Manufacturing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Antibodies Contract Manufacturing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Antibodies Contract Manufacturing Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Samsung Biologics and LegoChem Biosciences Forge Strategic Alliance to Accelerate ADC Innovation for Solid Tumor Treatment
13.3.2. Aragen Invests USD 30 Million in Bangalore Facility to Boost Biologics Manufacturing Capabilities
13.3.3. KBI Biopharma Unveils SUREmAb, Monoclonal Antibody Development with Accelerated Manufacturing Solutions
13.4. Strategy Analysis & Recommendation
14. Competitive Portfolio
14.1. Key Company Profiles
14.2. Key Product Portfolio
List of Figures
FIGURE 1. ANTIBODIES CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
FIGURE 2. ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ANTIBODIES CONTRACT MANUFACTURING MARKET DYNAMICS
FIGURE 7. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
FIGURE 10. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
FIGURE 12. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 14. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. ANTIBODIES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 24. ANTIBODIES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANTIBODIES CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MICROBIAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT & QUALITY CONTROL, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT & QUALITY CONTROL, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICALS COMPANIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICALS COMPANIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 34. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 35. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 36. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 37. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 38. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 39. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 40. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 41. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 42. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 43. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 44. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 45. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 46. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 47. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 48. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 49. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 50. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 51. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 52. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 53. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 54. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 55. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 56. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 57. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 58. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 59. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 60. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 61. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 62. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 63. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 64. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 65. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 66. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 67. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 68. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 69. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 70. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 71. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 72. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 73. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 74. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 75. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 76. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 77. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 78. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 79. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 80. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 81. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 82. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 83. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 84. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 86. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 88. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 90. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 92. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 94. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 95. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 96. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 97. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 98. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 99. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 100. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 101. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 102. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 103. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 104. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 105. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 106. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 107. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 108. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 109. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 110. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 111. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 112. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 113. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 114. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 115. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 116. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 117. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 118. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 119. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 120. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 121. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 122. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 123. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 124. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 125. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 126. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 127. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 128. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 129. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 130. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 131. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 132. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 133. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 134. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 135. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 136. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 137. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 138. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 139. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 140. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 141. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 142. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 143. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 144. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 145. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 146. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 147. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 148. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 149. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 150. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 151. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 152. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 153. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 154. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 155. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 156. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 157. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 158. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 159. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 160. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 161. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 162. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 163. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 164. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 165. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 166. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 167. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 168. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 169. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 170. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 171. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 172. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 173. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 174. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 175. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 176. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 177. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 178. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 179. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 180. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 181. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 182. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 183. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 184. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 185. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 186. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 187. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 188. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 189. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 190. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 201. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 202. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 203. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 204. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 205. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 206. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 207. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 208. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 209. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 210. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 211. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 212. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 213. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 214. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 215. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 216. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 217. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 218. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 219. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 220. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 221. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 222. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 223. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 224. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 225. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 226. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 227. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 228. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 229. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 230. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 231. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 232. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 233. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 234. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 235. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 236. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 237. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 238. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 239. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 240. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 241. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 242. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 243. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 244. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 245. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 246. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 247. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 248. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 249. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 250. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 251. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 252. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 253. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 254. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 255. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 256. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 257. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 258. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 259. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 260. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 261. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 262. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 263. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 264. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 265. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 266. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 267. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 268. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 269. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 270. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 271. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 272. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 273. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 274. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 275. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 276. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 277. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 278. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 279. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 280. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 281. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 282. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 283. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 284. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 285. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 286. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 287. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 288. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 289. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 290. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 291. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 292. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 293. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 294. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 295. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 296. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 297. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 298. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 299. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 300. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 301. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 302. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 303. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 304. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 306. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 308. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 310. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA ANTI

Companies Mentioned

  • Abeomics
  • Absolute Antibody by LSBio
  • Advanced ChemTech, Inc.
  • AGC Biologics
  • Antibodies, Inc.
  • AstraZeneca
  • Boehringer Ingelheim Biopharmaceuticals GmbH.
  • Bryllan LLC
  • Catalent, Inc.
  • CD BioSciences
  • Charles River Laboratories International, Inc.
  • Eli Lilly and Company
  • FUJIFILM Holdings Corporation
  • Fujirebio Inc. by H.U. Group Holdings, Inc.
  • Hycult Biotechnology (H.B.T.) B.V.
  • Labcorp Drug Development
  • Lonza Group Ltd.
  • Merck KGaA
  • Molecular Depot LLC
  • Pierre Fabre S.A
  • Samsung Biologics
  • Sapphire Bioscience Pty. Ltd.
  • Scantibodies Laboratory, Inc.
  • Synthon International Holding B.V.
  • The Serum Institute of India
  • WuXi Biologics Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 18.04 Billion
Forecasted Market Value ( USD ) by 2030 $ 33.56 Billion
Compound Annual Growth Rate10.8%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Global Research Antibodies & Reagents Market by Product (Antibodies, Reagent), Technology (Enzyme-linked Immunosorbent Assay, Flow Cytometry, Immunofluorescence), Indication, Application, End User - Forecast 2024-2030 - Product Image

Global Research Antibodies & Reagents Market by Product (Antibodies, Reagent), Technology (Enzyme-linked Immunosorbent Assay, Flow Cytometry, Immunofluorescence), Indication, Application, End User - Forecast 2024-2030

  • Report
  • 198 Pages
  • Global
From
Global Research Antibodies Market by Indication (Immunology, Infectious Diseases, Neurobiology), Operation (Drug Development, Genomics, Proteomics), Product, Source, Technology, Type, End User - Forecast 2024-2030 - Product Image

Global Research Antibodies Market by Indication (Immunology, Infectious Diseases, Neurobiology), Operation (Drug Development, Genomics, Proteomics), Product, Source, Technology, Type, End User - Forecast 2024-2030

  • Report
  • 188 Pages
  • Global
From
Research Antibodies & Reagents Market by Product (Antibodies (Type, Form, Source, Research Area), Reagents), Technology (Western blot, Flow Cytometry, ELISA), Application (Proteomics, Genomics), End User (Pharma, Biotech, CROs) & Region - Global forecast to 2028 - Product Image

Research Antibodies & Reagents Market by Product (Antibodies (Type, Form, Source, Research Area), Reagents), Technology (Western blot, Flow Cytometry, ELISA), Application (Proteomics, Genomics), End User (Pharma, Biotech, CROs) & Region - Global forecast to 2028

  • Report
  • 385 Pages
  • Global
From
Research Antibodies Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Research Antibodies Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Global Research Antibodies and Reagents Market 2023 - 2030 by Technology, Application, End-user, Product - Partner & Customer Ecosystem Competitive Index & Regional Footprints - Product Image

Global Research Antibodies and Reagents Market 2023 - 2030 by Technology, Application, End-user, Product - Partner & Customer Ecosystem Competitive Index & Regional Footprints

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.